Company / Capital Expenditures
Immunome Inc. Capital Expenditures History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$9.7M
FY2025
5-year range
$79.0K / $9.7M
FY2021-FY2025
Trend
+1065.5%
vs FY2024
Sector context
#59 of 194
Health Care
What the data says
Capital Expenditures changed +1065% YoY in FY2025, a notable deviation from the 6-year average annual change of +263%.
Based on SEC 10-K filings.
$10M in FY2025 with a 5-year CAGR of +75.2%.
Improved from $248,000 to $10M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +239.3%
- 5-Year CAGR
- +75.2%
- 10-Year CAGR
- -
Sector benchmark
#59 of 194 in Health CareTop 30% of 194This company $9.7M Sector average $117.5M
▼
-91.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +75.2%, indicating consistent growth.
- In FY2025, capital expenditures increased 1065.5% year-over-year.
- Ranks #59 out of 194 companies in the Health Care sector.
- Lowest capital expenditures in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score 4.19 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.7M | +1065.5% |
| FY2024 | $831.0K | +235.1% |
| FY2023 | $248.0K | +0.0% |
| FY2022 | $248.0K | +213.9% |
| FY2021 | $79.0K | -86.5% |
| FY2020 | $586.0K | +151.5% |
| FY2019 | $233.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026